Novavax Stock News

Shipments of Nuvaxovid to additional EU member states from the company''s Netherlands distribution centre are expected to quickly follow, adding to the stockpile of the region as it struggles with a surge in infections due to the Omicron variant

Health experts hope the availability of the protein-based vaccine will push Australia’s world-leading vaccination rate even higher.

Russian markets are crashing for a good reason, but global stocks and U.S. equities could feel more pain. Click here to learn more about this situation.

US biotech firm Novavax started shipping their Novaxovid COVID-19 vaccines to EU member states on Wednesday (23 February). The first protein-based vaccine available in Europe is expected to raise vaccination rates, but its efficiency against omicron is yet to be determined.

Thursday''s top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi Technologies.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips NVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years. The post Novavax Is a Buy on Recent Developments and Cheap Valuation appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” Get in Now on Tiny $3 ‘Forever Battery’ Stock Interested in Crypto? Read This First…

German Health Insurer Reveals ''Alarming'' Underreporting Of Vaccine Side-Effects A large German health insurance provider revealed on Wednesday that Covid-19 vaccine side-effects are vastly underreported, according to Welt . After analyzing data from over 10 million individuals, BKK ProVita board member Andreas Schöfbeck, over a 7.5 month period beginning in early 2021, 216,695 policyholders out of 10.9 million were treated for vaccine side-effects. This compares to 244,576 reports out of 61.4 million reported by the Paul Ehrlich Institute - a German federal agency. Germany has a population of around 83 million people. Schöfbeck called the data an "alarm signal," adding "The numbers determined are significant and urgently need to be checked for plausibility." " The data available to our company gives us reason to believe that there is a very considerable under-recording of suspected cases of vaccination side-effects after they received the [COVID-19] vaccine. " “If these figures are applied to the year as a whole and to” the entire population of Germany, Schöfbeck estimated, then “ probably 2.5-3 million people in Germany been under medical treatment because of vaccination side effects after [COVID-19] vaccination. ” As Jack Phillips of The Epoch Times notes: Schöfbeck concluded that based on their data, “there is a significant underreporting of vaccination side-effects ” in Germany.

British Columbia''s top doctor says she''s thrilled that the Novavax vaccine will soon be available in B.C., offering residents another option for getting vaccinated against COVID-19.

The company is hit with a pre-earnings target price cut from an analyst.